ArticleChina CDC weekly2026

A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years - China, 2021-2023.

Jingyu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.